Bio/Pharma News

Bayer Plans to Separate to Benefit Company Growth

September 18, 2014

Bayer separates into two entities to benefit the growth and development of Bayer Life Science and MaterialScience.

EMD Serono Collaborates with Sutro Biopharma to Develop ADCs

September 18, 2014

EMD Serono announces a collaboration with Sutro Biopharma to develop antibody drug conjugates for multiple undisclosed targets.

Baxter Names New Biopharmaceutical Company Baxalta

September 17, 2014

Baxter announced that its new biopharmaceutical company will be named Baxalta when the company separates into two publicly traded companies in mid-2015.

FDA Approves Treatment for Children with Hemophilia B

September 16, 2014

FDA approved Baxter International's treatment, RIXUBIS, for the treatment of children with hemophilia B.

EYLEA Receives FDA Breakthrough Therapy Designation

September 16, 2014

Regeneron Pharmaceuticals' injection for diabetic retinopathy in patients with diabetic macular edema received FDA breakthrough therapy designation on Sept. 16, 2014.

European Commission Grants Lilly and Boehringer Ingelheim's Insulin Glargine Product Marketing in EU

September 12, 2014

European Commission granted the first biosimilar insulin to receive regulatory approval in Europe.

FDA Approves XTANDI Capsules for Prostate Cancer

September 12, 2014

FDA approved XTANDI for the treatment of metastatic castration-resistant prostate cancer.

Merck Receives Accelerated Approval of the First FDA-Approved Anti-PD-1 Therapy

September 05, 2014

KEYTRUDA was approved for the treatment of unresectable or metastatic melanoma and disease progression.

AbbVie Announces Collaboration with Calico to Develop New R&D Facility

September 05, 2014

AbbVie and Calico announce a novel collaboration to accelerate the discovery, development, and commercialization of new therapies.

Pfizer to Acquire Vaccines from Baxter

July 30, 2014

Pfizer announced an agreement to acquire Baxter International?s marketed vaccines for $635 million.